TOMS Capital Investment Management LP Purchases New Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

TOMS Capital Investment Management LP purchased a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 4,015,000 shares of the company’s stock, valued at approximately $46,333,000. Roivant Sciences accounts for about 1.7% of TOMS Capital Investment Management LP’s holdings, making the stock its 10th largest position.

Other large investors have also modified their holdings of the company. Mutual of America Capital Management LLC boosted its position in Roivant Sciences by 0.4% during the 2nd quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock valued at $3,457,000 after acquiring an additional 1,142 shares in the last quarter. Acadian Asset Management LLC lifted its holdings in shares of Roivant Sciences by 23.2% during the 2nd quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock valued at $89,000 after purchasing an additional 1,603 shares during the last quarter. Covestor Ltd grew its stake in Roivant Sciences by 9.1% during the 3rd quarter. Covestor Ltd now owns 19,190 shares of the company’s stock valued at $222,000 after purchasing an additional 1,605 shares during the last quarter. US Bancorp DE raised its position in Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company’s stock worth $38,000 after buying an additional 1,948 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new position in shares of Roivant Sciences during the third quarter worth $35,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Price Performance

Shares of NASDAQ ROIV opened at $12.71 on Monday. The company has a market capitalization of $9.25 billion, a P/E ratio of 2.25 and a beta of 1.24. Roivant Sciences Ltd. has a 1 year low of $9.34 and a 1 year high of $13.06. The company has a 50 day simple moving average of $11.76 and a 200-day simple moving average of $11.38.

Wall Street Analyst Weigh In

Several research firms have commented on ROIV. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Finally, Bank of America lifted their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $17.93.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00. Following the sale, the chief operating officer now owns 606,525 shares of the company’s stock, valued at $6,865,863. The trade was a 14.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CAO Rakhi Kumar sold 250,000 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $11.89, for a total value of $2,972,500.00. Following the transaction, the chief accounting officer now owns 209,322 shares of the company’s stock, valued at approximately $2,488,838.58. This represents a 54.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,677,309 shares of company stock worth $43,283,184 over the last quarter. 7.90% of the stock is currently owned by company insiders.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.